Dekabank Deutsche Girozentrale Reduces $65K in ALX Oncology Holdings Inc. ($ALXO)
Key Points
- Dekabank Deutsche Girozentrale changed its ALX Oncology Holdings Inc. ($ALXO) stake by 100.0% last quarter, cutting to 0 shares.
- Wall Street's consensus rating on $ALXO is Strong Buy and an average price target of $4.60.
- $ALXO last traded around $1.58.
Dekabank Deutsche Girozentrale reduced its position in ALX Oncology Holdings Inc. ($ALXO), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 0 shares of ALX Oncology Holdings Inc. after selling 41,000 shares during the quarter.
ALX Oncology Holdings Inc. ($ALXO) Stock
ALX Oncology Holdings Inc. Earnings
Analysts Set New Price Targets
About ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.